Idarubicin surpasses gemcitabine and cisplatin in effectiveness.

In a study investigating treatment options for unresectable intrahepatic cholangiocarcinoma (ICCA), idarubicin exhibited the highest cytotoxicity among ten tested drugs, greatly outperforming the standard gemcitabine and cisplatin combination. Tumor growth was significantly inhibited in mouse models treated with idarubicin and gemcis, with pronounced effects particularly noted on days 12 and 15. Preliminary clinical findings also indicate that idarubicin-transarterial chemoembolization combined with gemcis may enhance survival rates for ICCA patients while maintaining safety.